Business Wire

Societal Impact of Pain Costs the EU up to 441 Billion Euros Annually

Del

Pain causes a problem for individuals as well as a challenge for healthcare systems, economies and society: each year, approximately one in five Europeans or 20 percent of the adult population in Europe are affected by chronic pain. This includes 153 million people suffering migraine or other disabling headaches, 200 million musculoskeletal disorders and 100 million people experiencing other forms of chronic pain. The estimated direct and indirect healthcare costs for chronic pain disorders in European Member States vary between two and three percent of GDP across the EU. For 2016, this estimate would result in up to 441 billion Euros. Therefore, in advance of the Societal Impact of Pain symposium, experts in pain care call upon European and national policymakers to improve pain care policies and boost the productivity of the European workforce.

The European Union and its member states are confronted with substantial challenges. On the one hand, the need to increase productivity and prevent involuntary early retirement, on the other hand, to provide a social system that cares for an ageing population. In early 2017, the discussion in the European Parliament on the European Semester for economic policy coordination led to a resolution. In this resolution the European Parliament expressed its concern about the effects of demographic developments on public finances, pensions and healthcare systems and warns that the already foreseeable funding costs will have a significant impact.

Experts estimate that half of all citizens living in the EU at some point in their lives suffer from back pain. Approximately 15 percent of these citizens with back pain are on sick leave for over one month. Worldwide chronic pain conditions (in particular back pain) are by far the greatest cause of disability. Unsurprisingly chronic pain is one of the major reasons why people exit the labour market prematurely and it contributes significantly to disability retirement.

Aside from its effect on the workforce, chronic pain is one of the top causes of disability in every region of Europe and increases the risks of other health problems, social exclusion and poverty. Stigma and lack of public knowledge worsen the burden on patients and families by preventing people in pain from seeking treatment. Large health inequalities persist in the EU as many patients do not have access to adequate pain treatment.

Although pan-European data comparing the impact of pain on health care systems are lacking, we know that pain disorders are amongst the most prevalent, costly and disabling conditions in the workplace. Analysis focussing on the impact of pain on labour force participation, absence from work (absenteeism) and attending work while sick (presenteeism) have demonstrated that the experience of pain had a substantial negative association with labour force participation in Europe.

Due to the effects of pain on rates of absenteeism, reduced productivity and even the risk of employees leaving the labour market, social protection systems spend a large budget on pain related complaints. Data from the Labour Force Survey shows that over 2.3 million people in the UK report conditions or disabilities related to their back or neck as their main health problem. In 2013, low back pain was ranked highest of all injury-related disabilities and yielded the largest total number of “Years Lived with Disability” throughout England. With more than 500 million sick days per year in Europe, musculoskeletal pain causes almost 50 percent of all absences from work lasting at least three days in the EU and 60 percent of permanent work incapacity.

Healthy citizens, on the other side, reduce the strain on healthcare systems and boost economic growth by staying active for longer. Effective pain policies can positively impact the productivity and longevity of Europe’s labour force and delay early retirement.

Under the auspices of the 2017 Maltese Presidency of the Council of the EU the Societal Impact of Pain symposium from June 7–9, 2017 will bring together more than 300 participants representing healthcare professionals, pain advocacy groups, researchers and specialists in the field of pain as well as insurers and budget holders. The SIP platform aims to create structured EU-wide cooperation with lasting political impact, to find solutions that improve the lives of those with chronic pain, but also minimize the impact of pain on society.

- Ends -

About the SIP-Platform

The Societal Impact of Pain (SIP) is an international, multi-stakeholder platform created as a joint initiative of the European Pain Federation EFIC® and Grünenthal with the aim to:

  • raise awareness of the relevance of the impact that pain has on our societies, health and economic systems
  • exchange information and sharing best-practices across all Member States of the European Union
  • develop and foster European-wide policy strategies for an improved pain management in Europe (Pain Policy).

Over 300 international and national pain advocacy groups, scientific organisations and authorities have endorsed the scientific aims of SIP symposia and meetings.

The scientific framework of the “Societal Impact of Pain” (SIP) platform is under the responsibility of the European Pain Federation EFIC ®. Cooperation partners for SIP 2017 are Pain Alliance Europe (PAE) and Active Citizenship Network (ACN). The SIP 2017 symposium is co-hosted by the Malta Health Network and the No Pain Foundation. The pharmaceutical company Grünenthal GmbH is responsible for funding and non-financial support (e.g. logistical support). In the past the scientific aims of the SIP symposia have been endorsed by over 300 international and national pain advocacy groups, scientific organisations and authorities.

References can be provided upon request

You can find more information at www.SIP-Platform.eu

Contact information

Grayling for SIP
Sabrina Kieback
Sabrina.kieback@grayling.com
+49 (0)69 96 22 19 52)

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13Pressemelding

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21Pressemelding

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38Pressemelding

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00Pressemelding

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 09:00Pressemelding

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom